Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaShanshan Pei, Craig T. Jordan, Haobin Ye et al.|Cancer Discovery|2020Cited by 550
Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem CellsCourtney L. Jones, Craig T. Jordan, Shanshan Pei et al.|Cell stem cell|2020Cited by 228
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyNeil P. Shah, Kristina M. Gregory, Jennifer E. Vaughn et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 116
CML and the WHO: Why?Ellin Berman, Brian Druker, Jennifer E. Vaughn et al.|Journal of Clinical Oncology|2023Cited by 14
Targeting MDS Stem Cells with Omacetaxine and Azacitidine for Newly Diagnosed High Grade Patients: Phase 1 Trial Results and Preliminary Mechanistic StudiesBrett M. Stevens, Daniel A. Pollyea, Amanda Winters et al.|Blood|2021Cited by 0